Saturday 17 October 2026
Export RVP’s income statement to Excel — free account
Retractable Technologies, Inc.
RVP Healthcare Medical Instruments & Supplies
Retractable Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.3 million, up 15.8% from fiscal 2024. In the quarter to June 2026, revenue fell 31.1%, EPS was flat, free cash flow grew 56.7% and total debt fell 32.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.58
0.01
−1.69%
Follow RVP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.66 | 0.60 | 0.53 | 0.64 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(19.99) | (38.64) | (14.44) | (12.44) | |
P/B ratio |
0.33 | 0.31 | 0.28 | 0.30 | |
Price to Tangible BV |
0.33 | 0.31 | 0.28 | 0.30 | |
EV/Sales |
(0.21) | (0.34) | (0.41) | (0.52) | |
EV/EBITDA |
0.59 | 0.97 | 1.01 | 1.18 | |
EV/Operating CF |
1.03 | 1.84 | 2.16 | 3.55 | |
EV/FCF |
0.93 | 1.71 | 2.03 | 3.45 | |
Quick Ratio |
4.47 | 4.71 | 4.11 | 3.68 | |
Current Ratio |
6.66 | 6.57 | 5.74 | 4.93 | |
Net Debt/EBITDA |
18.44 | 6.48 | 8.17 | 12.05 | |
Debt/Assets |
0.67% | 0.63% | 0.59% | 0.51% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.25 | 0.25 | 0.26 | 0.23 | |
Operating CF/Net income |
(4.01) | 0.25 | 0.32 | (0.62) | |
Capex/Depreciation |
(0.05) | (0.01) | 0.00 | (0.02) | |
Interest Coverage |
(177.38) | (357.11) | (302.35) | (275.18) | |
Research and Development Expense of Revenue |
1.98% | 1.32% | 2.37% | 2.60% | |
Selling, General and Administrative Expense of Revenue |
50.97% | 54.08% | 71.88% | 71.51% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.22) | (0.22) | (0.38) | (0.13) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(25.00%) | (54.55%) | (31.82%) | (16.67%) | |
Free Cash Flow Yield |
(33.32%) | (32.97%) | (37.51%) | (23.70%) | |
Revenue per Share |
0.34 | 0.32 | 0.24 | 0.24 | |
Operating CF per Share |
(0.04) | (0.02) | (0.05) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.02) | (0.05) | (0.06) | |
Cash per Share |
1.13 | 1.24 | 1.19 | 1.33 | |
Shareholders Equity per Share |
2.56 | 2.48 | 2.34 | 2.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.56 | 2.48 | 2.34 | 2.43 | |
Free Cash Flow |
(1.35) | (0.62) | (1.37) | (1.76) | |
Working Capital |
54.50 | 53.49 | 49.51 | 52.56 | |
Capital Expenditures |
(0.09) | (0.03) | (0.01) | (0.03) | |
Net Current Asset Value |
(5.53) | (5.17) | (7.54) | (2.91) | |
EV/EBIT |
0.38 | 0.62 | 0.66 | 0.78 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.44 | 8.49 | 6.67 | 9.04 | |
Average Payables |
3.91 | 4.82 | 5.05 | 5.38 | |
Average Inventory |
20.85 | 18.19 | 18.81 | 18.19 | |
Average Assets |
152.12 | 151.68 | 143.45 | 144.39 | |
Average Common Equity |
79.89 | 80.54 | 73.12 | 74.44 |
Columns are period end dates